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Thegutmicrobiotaplaysacrucialroleinmaintaininghealth.Alterationsofthegutbacterialpopulationhavebeenassociatedwitha
numberofdiseases.Pastandrecentstudiessuggestthatonecanpositivelymodifythecontentsofthegutmicrobiotabyintroducing
prebiotics, probiotics, synbiotics, and other therapeutics. This paper focuses on probiotic modulation of the gut microbiota by
their delivery to the lower gastrointestinal tract (GIT). There are numerous obstacles to overcome before microorganisms can be
utilized as therapeutics. One important limitation is the delivery of viable cells to the lower GIT without a signiﬁcant loss of cell
viability and metabolic features through the harsh conditions of the upper GIT. Microencapsulation has been shown to overcome
this, with various types of microcapsules available for resolving this limitation. This paper discusses the gut microbiota and its role
in disease, with a focus on microencapsulated probiotics and their potentials and limitations.
1.Introduction
Thegutmicrobiota,whichresidesinthegastrointestinaltract
(GIT) and is also termed microﬂora, plays an important
role in human health and disease. The GIT is comprised of
the stomach, the duodenum, the jejunum, the ileum, the
colon, the rectum, and the anal canal. The lower digestive
tract, speciﬁcally the colon, is the primary site of importance
for bacterial cell colonization; however, upper digestive
tract microorganisms are also of importance. The bacterial
population of the gut has been studied in diseases such as
colon cancer, inﬂammatory bowel diseases (IBD), hyper-
cholesterolemia, nonalcoholic fatty liver disease (NAFLD)
and others. Certain bacterial populations, such as lactic acid
bacteria, have been shown to positively inﬂuence health.
Hence, attempts to modify the microﬂora, towards those
bacteria, for disease treatment and prevention should prove
advantageous. For this purpose, prebiotics, probiotics, and
synbiotics have been used. The delivery of viable probiotic
bacteria is impeded by the harsh conditions of the upper
GIT, hence, a vessel for delivering optimum cell viability to
the lower GIT is required. Microcapsules can be used as a
vehicle with the capability to protect the viability and activity
of orally delivered bacterial cells through the upper GIT.
This paper will ﬁrst give an overview of the gut micro-
biota and its main characteristics, focusing on its role in
colon cancer, IBD, and hypercholesterolemia. Modulation of
the gut microbiota to promote health will then be described
throughtheuseofprobiotics,prebiotics,andsynbiotics,with
probiotics as a main focus. Microencapsulation and types of
microcapsules will be described along with their success in
the treatment and prevention of diseases. Finally, the paper
will conclude with a discussion on this ﬁeld’s future.
2. The GastrointestinalBacterialSystem
The gut microbiota contains a broad spectrum of microor-
ganisms, totalling 1013 to 1014 bacterial cells, but has not
been completely explored as of yet [1]. The importance of
the gut microﬂora is exempliﬁed by the fact that the number
of bacterial cells outnumbers human cells by a factor of
ten [2]. The human intestinal habitat contains 300 to 500
diﬀerent species of bacteria, varying signiﬁcantly in content2 Journal of Biomedicine and Biotechnology
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Figure 1: The GIT characteristics (oxygen distribution, pH, bacterial populations, and bacterial cell counts) and the localization of the
various gut bacterial populations, termed microbiota.
betweenindividuals[3].Mostgutbacteriaresideinthelower
part of the digestive tract, in the large intestine, since the
uppertractconsistsofhighlevelsofacid,bile,andpancreatic
secretionswhicharetoxictomostmicroorganisms,asshown
in Figure 1 [3]. Even though some bacterial species of the
gutarepotentialpathogens,theconstantinteractionbetween
the host and its microbes usually remains beneﬁcial to
the health of the host [4]. It has been demonstrated that
the gut bacterial population plays an important role in
their host’s metabolism and energy consumption, especially
in the digestion and absorption of nutrients [1, 5]. The
upper portion of the GIT, made up of the stomach and
the duodenum, harbours very low numbers of microor-
ganisms, with less than 1000 bacterial cells per gram of
contents, with the predominant microorganisms present
being Lactobacilli and Streptococci [6, 7]. The relatively low
number of microorganisms found in the upper digestive
tract, although some are of great importance in human
disease, can be explained by the presence of high levels
of acid, bile, and pancreatic secretions, as aforementioned
[7,8]. One important organismfoundin the stomach,which
can withstand these harsh conditions, is Helicobacter pylori,
a microorganism responsible for ulcers and stomach cancer
[9]. There is also a phasic propulsive motor activity in the
upper GIT which impedes any stable bacterial colonization
[10]. Lower in the digestive tract are found the jejunum and
the ileum where there is a gradual increase in the bacterial
numbers from 104 to approximately 107 cells per gram of
contents by the time the distal ileum is reached [7]. Once in
thelargeintestine,thetractisheavilypopulatedbyanaerobes
with up to 1012 cells per gram of luminal contents [10]. This
paper focuses on the lower part of the digestive tract, due to
its abundant bacterial population.
Bacteria are classiﬁed into genera and species based on
their individual phenotypic and genotypic characteristics,
with a number of diﬀerent genera found actively residing
in the human GIT. The dominant anaerobic genera are
Bacteroides, Biﬁdobacterium, Eubacterium, Clostridium, Pep-
tococcus, Peptostreptococcus, and Ruminococcus [4, 11]. The
main genera of facultative anaerobic bacteria are Escherichia,
Enterobacter, Enterococcus, Klebsiella, Lactobacillus, and Pro-
teus [4, 11]. The proportion and numbers of these bacteria
can vary, depending on a number of genetic and envi-
ronmental factors, including disease state and one’s food
intake [1, 11–13]. The main functions of the microﬂora were
mostly elucidated by investigations with animals bred under
germ-free conditions, with the functions broadly qualiﬁed as
metabolic, trophic, and protective [3, 14, 15].Journal of Biomedicine and Biotechnology 3
The gut microbiota has a signiﬁcant impact on host me-
tabolism, participating in microbial-mammalian co-metab-
olism. The microbiota is considered a multifunctional organ
with metabolic capabilities that humans have not yet fully
evolved into their own genomes [16]. It has the ability
to break down indigestible plant polysaccharides, termed
dietary ﬁbers and also plays an important role in the
biotransformation of conjugated bile acids, described in
more detail later in this paper [17–20] .T h ei m p o r t a n c eo f
the gut microbiota in vitamin synthesis was demonstrated
many years ago with the use of germ-free animals [21].
Experiments on a chick animal model demonstrated the
synthesis of riboﬂavin, vitamin B, pantothenic acid, vitamin
B12, folic acid, nicotinic acid, thiamine, and biotin by the gut
microbiota [22]. Furthermore, Pseudomonas and Klebsiella
sp.,tworesidentorganismsofthesmallintestine,werespecif-
ically shown to synthesize signiﬁcant amounts of vitamin B12
[23]. As described, the gut microbiota has extensive roles to
play in normal human metabolism.
3. The GutMicrobiota andIts Role in
HumanHealthandDisease
The gut microbiota has gained importance in disease aetiol-
ogy and pathology, with emerging evidence demonstrating
its role in disease [1, 24]. A number of diseases have been
associated with alterations of the gut microbiota, and if one
can elucidate the exact link between the two one can begin
to successfully treat and prevent these disorders through the
modulationofthenumberand/orspeciesofmicroorganisms
present. Some disorders associated with the microﬂora
include colon cancer, IBD, hypercholesterolemia and nonal-
coholic fatty liver disease, among others [13, 24–28].
3.1. Role of the Gut Microbiota in Colon Cancer. Colorectal
cancer is the second most common cause of cancer death
in men and women [29]. Although the genetic mechanisms
of colorectal cancer are well established, there are several
environmental factors that have also been implicated in the
development of sporadic colon carcinomas [3, 30]. Foods,
such as processed meats, which contain high levels of dietary
fat, have been associated with an increased risk of colon
cancer development when compared to the risk associated
with a high intake of fruits, vegetables, grains, and ﬁsh [30,
31]. It was proposed that the eﬀect of diet could be mediated
by changes in the composition of the colonic microﬂora
such that the intestinal bacteria are responsible for the
initiation of colon cancer [3, 13]. Data shows that bacteria
of the Bacteroides and Clostridium genera were associated
with an increase in the incidence and growth rate of colonic
tumors in tumor-induced animals, while genera such as Lac-
tobacillus and Biﬁdobacterium (well-characterized bacteria
predominantly used in therapeutic probiotic formulations)
appeared to prevent tumorigenesis [32, 33]. The properties
of the colonic microﬂora make it a promising target for the
development of a colon cancer therapeutic [34].
3.2. Inﬂammatory Bowel Disease and the Gut Microbiota.
IBD, prominent in Western countries, is made up of a group
of disorders that are characterized by a chronic and relapsing
inﬂammation of the GIT [35]. The two most prominent
forms of IBD are Crohn’s Disease (CD) and ulcerative colitis
(UC), with the bacterial ﬂora as an important factor and
contributor of the inﬂammation [36, 37]. Suﬀerers of IBD
have a higher bacterial attachment to gut epithelial surfaces
when compared to that found in healthy individuals [38].
The link between intestinal mucosal inﬂammation and the
resident bacteria has been further demonstrated, in vivo,
using rats and mice treated with broad-spectrum antibiotics
[39]. This treatment mitigates, although only temporarily,
mucosal inﬂammation in animals with IBD, suggesting that
the resident bacteria are causing the inﬂammation [39].
Furthermore, an overpopulation of the Bacteroides genera
on the gut epithelium leads to an increased occurrence of
transmural inﬂammatory lesions [3]. Early research demon-
strated that the presence of Escherichia coli is linked to active
UC and contributes to the development of inﬂammation
[40]. E. coli has also been linked to CD, with the presence of
speciﬁcadherent-invasivespeciesfoundintheresectedileum
of patients [41, 42]. This eﬀect appears to be species speciﬁc
asonlycertainphylogeneticgroupsofE.coliwerefoundtobe
more frequent in UC and CD patients when compared with
healthy controls [43, 44]. It is clear that the gut microﬂora
plays an important role in IBD pathology and an eﬃcient
therapy is still required.
3.3. Gut Microbial System and Hypercholesterolemia. Hyper-
cholesterolemia is a disorder whereby an individual demon-
strates an elevated serum cholesterol level. For many decades
now this disorder has been recognized as a signiﬁcant risk
factor associated with atherosclerosis and coronary heart
disease [45]. Current treatment options to lower serum
cholesterol levels involve the use of pharmacological agents
such as statins which act by inhibiting HMG-CoA reductase,
the rate-limiting enzyme of cholesterol biosynthesis [46].
Statins make up a group of compounds that are generally
well tolerated but remain expensive and have signiﬁcant
side-eﬀects, including gastrointestinal problems, such as
diarrhoea, but may also include severe liver and skeletal
abnormalities [47–49]. Bearing the potential signiﬁcant con-
sequences of hypercholesterolemia in mind, the importance
of the gut microbiota in cholesterol metabolism and the
pathogenesis of hypercholesterolemia, a new paradigm is
suggested for the development of a successful treatment.
As early as 1959, research was performed to elucidate the
role of the gut microbiota in cholesterol homeostasis with
researchers demonstrating that germ-free rats, administered
adietwithoutsigniﬁcantamountsofcholesterol,nonetheless
showed higher serum-cholesterol values than control rats
administered the same diet [50]. Several mechanisms have
been proposed as methods by which the gut microbiota
may modulate cholesterol levels within the host [51]. Recent
developments have demonstrated that the composition of
the microbiota and diet is directly correlated with cholesterol
levels in vivo, speciﬁcally, the number of Biﬁdobacteria
found in the gut is positively correlated with higher levels
of high-density lipoprotein (HDL) [52–54]. In contrast,
the number of Coriobacteriaceae is correlated with higher4 Journal of Biomedicine and Biotechnology
levels of non-HDL cholesterol [53]. Gut microbial activities
inﬂuence lipid metabolism, bearing a signiﬁcant impact
on hypercholesterolemia, by the modiﬁcation of bile acid
metabolic patterns, by impacting the emulsiﬁcation, absorp-
tion, and storage properties of bile acids and by inﬂuencing
the lipoperoxidation through bile acid signalling properties
[19]. With these facts in mind, the modulation of the gut
microbiota could potentially decrease hypercholesterolemia
in aﬀected patients.
4. Modulation of the Gut Microbiota for
Human Health Beneﬁts
Past and current research has demonstrated that the gut
microbiota plays an important role in the pathogenesis of
a number of diseases. Certain bacteria, considered “good,”
such as Biﬁdobacteria and Lactobacilli, are shown to be
correlated with a decrease in the occurrence of a number
of disorders, suggesting that the targeted increase of these
beneﬁcial bacteria could decrease the incidence and severity
of prominent diseases. The colonic delivery of prebiotics
and probiotics are methods that have been successfully
used to modify the gut microbiota. Antibiotics can prove
beneﬁcial in short-term use but their prolonged use may
result in signiﬁcant side-eﬀects. An important concern
is the development of bacterial resistance which reduces
the eﬀectiveness of the therapy and further predisposes
the patient to life-threatening illnesses caused by potential
pathogens with increased resistance to the antibiotic.
Current research focuses on prebiotics, probiotics, and a
combination of both, termed synbiotics for modulating the
gut microbiota. The Food and Agriculture Organization of
the United Nations deﬁnes a prebiotic as a “non-viable food
component that confers a health beneﬁt on the host, asso-
ciated with a modulation of the microbiota” [55]. Prebiotic
molecules consist of naturally occurring or synthetic sugars
used by certain colonic bacteria, especially Biﬁdobacteria,a s
a carbon source for growth and metabolism [56]. Numerous
prebiotics have demonstrated their beneﬁcial eﬀects on
disease through modulators of the gut microbiota [57–61].
Prebiotic delivery nonspeciﬁcally increases the number of
“good bacteria” not acting at the species level, which may
be important in some disease states. On the other hand,
probiotics are a method by which the gut microbiota can
be speciﬁcally modulated for an individual to reestablish and
maintain a healthy state.
4.1. Modulation of the Gut Microbiota by Probiotics Can Pro-
mote Human Health. The FAO and WHO deﬁne probiotics
as “live microorganisms which, when administered in ade-
quate amounts, confer a health beneﬁt on the host” [62].
Probiotics are inexpensive, safe, free of long-term nega-
tive side-eﬀects, and have already demonstrated beneﬁcial
eﬀects for treating immunological, digestive, and respiratory
diseases [62]. Furthermore, these are naturally occurring
organisms found in foods such as milk and yoghurt and,
so, are widely accepted by the general public. The most
common types of probiotic microorganisms are the lactic
acid bacteria, important components of the healthy gut
microbiota and regarded as safe by the American FDA [63].
Other microorganisms occasionally used as probiotics are
yeastsandﬁlamentousfungi[63].Inthissection,wedescribe
the use of probiotics on colorectal cancer, IBD, hypercho-
lesterolemia and NAFLD.
Probiotics have been proposed and investigated as a
potential treatment/prevention method for colorectal can-
cer. Early studies demonstrated that 1,2-dimethylhydrazine-
(DMH-) induced colon cancer in rats showed a decrease
in mortality rate if the test animals were fed Streptococcus
thermophilus-fermented skim milk [94]. Another research
group demonstrated that Lactobacillus rhamnosus GG, in
lyophilizedformincorporatedinahigh-fatdiet,waseﬀective
at reducing tumor incidence in the rat DMH colon cancer
model [95]. Studies using Biﬁdobacterium longum also
demonstrated an inhibition of carcinogen-induced colon
cancers and precursor lesions [96, 97]. Additional studies
demonstrate a reduction of colon tumorigenesis markers
following the incorporation of Lactobacillus acidophilus in
a high-fat control diet in DMH colon cancer rats [98]. The
probiotics are suggested to achieve a protective eﬀect by
interacting with the carcinogen(s) in the intestinal lumen (in
the case of the DMH rat model, interaction with the DMH
metabolites azoxymethane or methylazoxymethane) leading
to a decrease in the potency/availability of the carcinogenic
compound [97, 98].
Probiotics have also been investigated as a method of
treatment for IBD. A trial in ulcerative colitis (UC) patients
was performed to study the eﬀect of the delivery of an oral
probiotic capsule on the remission of the disorder [99]. The
probiotic Biﬁdobacteria were administered following treat-
mentwithanUCstandardtherapy[99].Itwasdemonstrated
that 93.3% of the patients in the control group suﬀered
a disease relapse compared to only 20% of the patients
administered the probiotic capsule [99]. A signiﬁcant reduc-
tion in inﬂammation was also observed in the treatment
group when compared to the control group [99]. Another
study demonstrated the use of Faecalibacterium prausnitzii
as a probiotic for treating Crohn’s Disease (CD) [36]. F.
prausnitizii and its supernatant were both found to have
anti-inﬂammatory eﬀects in vitro using peripheral blood
mononuclear and colon adenocarcinoma cells and in vivo in
a mouse model of induced colitis [36]. A number of other
studies related to the eﬀects of probiotics on the prevention
and the treatment of IBD, described in another review, have
been done, with varying success [100].
Early studies suggest that probiotic bacteria may have
ab e n e ﬁ c i a le ﬀect on hypercholesterolemic patients, by
decreasing blood lipid levels [101]. A study was undertaken
with hypercholesterolemic mice administered low levels of
the probiotic Lactobacillus reuteri for a week [101]. The
mice demonstrated a decrease in cholesterol and triglyceride
levels and an increase in the HDL:LDL ratio [101]. A
study was also performed with hyperlipidemic patients who
were administered the probiotic Lactobacillus sporogenes over
a three-month period [102]. Following treatment, these
patients showed, on average, a 32% reduction in total
cholesterol levels accompanied with a 35% reduction inJournal of Biomedicine and Biotechnology 5
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LDL [102]. Studies have also demonstrated that the delivery
of certain strains of Lactobacilli can alleviate symptoms
associated with IBD [103, 104].
Probiotics have also been proposed as a potential treat-
ment option for NAFLD because of their modulating eﬀect
onthegutﬂorathatcouldinﬂuencethegut-liveraxistowards
a healthy state. NAFLD is characterized by the release of
inﬂammatory cytokines and commensal bacteria have been
shown to provoke anti-inﬂammatory responses from the
gut epithelia, suggesting a mechanism of action to treat
the disease [105]. Probiotics can have an inhibitory impact
on the development of NAFLD by a number of mecha-
nisms: competitive inhibition of pathogenic bacterial strains,
alteration of the inﬂammatory eﬀects of pathogenic strains
through changes in cytokine signalling, improvement of the
function of the epithelial barrier and direct decreases of
proinﬂammatory cytokines, including TNF-α [105]. VSL#3
is a high-potency medical food probiotic made up of a
number of diﬀerent bacterial strains [106]. These strains
make up 450 billion live lactic acid bacteria per packet: Biﬁ-
dobacterium breve, Biﬁdobacterium longum, Biﬁdobacterium
infantis, Lactobacillus acidophilus, Lactobacillus plantarum,
Lactobacillus paracasei, Lactobacillus bulgaricus, and Strepto-
coccusthermophilus[106].Thiscombination,inbothmurine
and human trials, demonstrated all of the mechanisms
described as potential beneﬁcial targets for the treatment
of NAFLD [107]. Murine models of acute liver injury
have also shown a decrease in hepatic injury following the
administration of various Lactobacillus and Biﬁdobacterium
species [108–110].
There are a number of mechanisms by which probiotics
could be exerting their beneﬁcial eﬀects, as shown in
Figure 2. The mechanisms include (1) by the production
of pathogen inhibitory substances; (2) by the blocking of
pathogenic bacteria adhesion sites; (3) by nutrient compe-
tition and production; (4) by the degradation of toxins and
toxin receptors; (5) by the modulation of immune responses
[104].6 Journal of Biomedicine and Biotechnology
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Figure 3: The concept of microcapsules for probiotic delivery. (a) Alginate-Poly-L-Lysine (APA) and (b) Genipin Crosslinked Alginate
Chitosan (GCAC) microcapsules.
4.2. System for Delivering Probiotics to the GIT. Probiotics
must be delivered to the target sites in suﬃcient number
and metabolic active phase to be eﬀective. Currently avail-
able probiotic formulations are excellent but have serious
limitations. One of the major limitations is the delivery of
probiotics to the lower GIT, with the presence of acids and
bile greatly hindering the viability of the probiotics as they
travel through the gut (speciﬁcally the acidic environment of
thestomach).Adelivery systemis, hence,requiredtosurpass
this obstacle. Another complication is the presence of an
immune system which can be induced and potentially attack
the delivered cells. Hence, a method is required to protect
the probiotic cells while maintaining high levels of probiotic
viability and activity when delivered in the GIT. There are
many methods available, each with its own limitations.
This paper introduces microencapsulation and discusses its
potentialsandlimitationsinbacterialcelldeliverytotheGIT.
5. Microencapsulationand
Deliveryof Probiotics
Microencapsulation is a method deﬁned as the “entrapment
of a compound or a system inside a dispersed material for its
immobilization, protection, controlled release, structuration
and functionalization” [111]. There exists a great variety of
microcapsules which can diﬀer in size, composition, and
function, depending on the ﬁnal goal of the encapsulated
product. Microcapsules can be used to entrap all sorts of
substances: solids, liquids, drugs, proteins, bacterial cells,
stem cells, and so forth [112–114]. With such a range of
substances that can be entrapped, microcapsules can have an
assortment of objectives and applications, whether for drug
delivery, enzyme retrieval, artiﬁcial cell and artiﬁcial organ
delivery or, as described in this review, for the delivery of live
probiotic bacteria.
Thereareanumberofmicrocapsuledeliverysystemsthat
have been proposed for the oral delivery of live bacterial
cells, as detailed in Table 1.S u na n dG r i ﬃths investigated
the use of acid-stable beads made of gellan and xanthan
gum for the immobilization of Biﬁdobacterium [84]. The
researchgroupdemonstratedthatimmobilizedcellssurvived
signiﬁcantly better than free cells after refrigeration in
pasteurized yogurt for a period of 5 weeks [84]. One com-
mon encapsulation method, for viable cell immobilization,
utilizes calcium alginate as a polymer [115]. However, one
prominent diﬃculty encountered with the use of alginate
beads is that these, alone, are not acid resistant and upon
exposure to the low pH conditions encountered in the
stomach, display signiﬁcant shrinkage and a decrease in
mechanical strength [64]. A number of methods utilizing
polymer cross-linking have been suggested, including for-
mulations using carrageenan, alginate-poly-L-lysine, starch
polyanhydrides, polymethacrylates, and enteric coated poly-
mers [116]. Microencapsulation methods are still being
developedandoptimizedtoallowforincreasedgastrointesti-
nal survival and immunoprotection. One newly developed
type of microcapsule that shows promising results in terms
of mechanical stability and pH resistance is the genipin-
crosslinked-alginate-chitosan (GCAC) microcapsule, shown
in Figure 3 [87, 117].
One of the most commonly utilized and characterized
formulations for microencapsulation is the alginate-poly-
L-lysine-alginate (APA) microcapsule [118]. This type of
microcapsule has been used for many applications including
drug, stem cell, and bacterial cell delivery. This method relies
on a polyelectrolyte complexation mechanism for the asso-
ciation of the polymers, alginate and poly-L-lysine (PLL).
Alginate is a naturally occurring biocompatible polymer,
extractedfrombrownalgae,thatisincreasinglybeingusedin
the biotechnology industry for a wide range of applications
[119]. Alginate is an unbranched polysaccharide which con-
tains 1,4 -linked β-D-mannuronic acid and α-L-guluronic
acid blocks which are interdispersed with regions of the
alternating structure, β-L-mannuronic acid-α-L-guluronic
acid blocks [120] .P L Li sap o l y p e p t i d em a d eu po ft h e
amino acid L-lysine that is available in a variable number
of chain lengths, determined by its molecular weight. It is
a polycationic polymer that can be used during the coating
step of microencapsulation. The addition of this polymer
leads to the formation of a capsule membrane that provides
selective permeability and immunoprotection. The alginate
bead could not withstand the harsh conditions of the GIT
in the absence of PLL, which provides it with an increased
mechanical stability.Journal of Biomedicine and Biotechnology 7
Table 1: Types of microcapsules available for the targeted delivery
of probiotic bacteria.
Types of Microcapsules Bacteria Reference(s)
Alginate Beads
L. rhamnosus
B. longum
L. salivarius
L. plantarum
L. acidophilus
L. paracasei
L. casei
B. lactis
L. reuteri
[64–70]
Alginate-cellulose
acetate phthalate
B. lactis
L. acidophilus [71]
Alginate-chitosan B. animalis subsp. lactis
L. bulgaricus [72, 73]
Alginate-chitosan-Acryl-
Eze B. animalis subsp. lactis [72]
Alginate-chitosan-
alginate
B. biﬁdum
L. casei [64]
Alginate-chitosan-
Sureteric B. animalis subsp. lactis [72]
Alginate-coated gelatin B. adolescentis
B. pseudolongum [74]
Alginate-poly-L-lysine-
alginate
B. biﬁdum
L. reuteri
L. casei
[64, 75]
Alginate-starch
L. acidophilus
B. lactis
B. infantis
L. casei
[76–78]
Gelatin-gum
arabic-soluble starch
B. infantis
B. longum [79–81]
Gelatin-toluene-2-4-
diisocyanate L. lactis [82]
Gellan-alginate B. biﬁdum [83]
Gellan-xanthan
B. adolescentis
B. biﬁdum
B. breve
B. infantis
B. lactis
B. longum
[84–86]
Genipin-crosslinked-
alginate-chitosan L. plantarum [87]
Pectin-casein B. lactis
L. acidophilus [88]
Potato starch
granules-amylose B. longum [89]
Whey protein
B. breve
B. longum
L. rhamnosus
[90, 91]
κ-carageenan
B. longum
S. thermophilus
L. bulgaricus
S. lactis
[92, 93]
Thereareanumberofdiﬀerentmethodsusedtofabricate
microcapsules. The microencapsulation technique employed
is determined by the type and the size of microcapsules
one wants to obtain. The characteristics of the microcapsule
must also take into consideration the function that the
microcapsule will ultimately undertake. There are generally
three main stages to the process of microencapsulation.
The ﬁrst step is the incorporation of the ingredients into
a solution by mixing or dispersion, to make up the core
of the microcapsule. This is then followed by mechanical
operations, such as spraying or emulsiﬁcation, to form
the droplets. The ﬁnal step of microencapsulation involves
product stabilization through coating, followed by a num-
ber of physical or chemical processes [111]. Each step
of microencapsulation can be optimized according to the
desired characteristics of the ﬁnal formulation.
6. MicroencapsulatedProbiotics
There has been strong interest in the ﬁeld of microencapsu-
lated probiotics. Research has shown that microencapsulated
probiotics keep their viability better than free cells under
stress in GIT deliveries. Research into the applications of
microencapsulated probiotics is also ongoing, with promis-
ing results for the eventual treatment of a number of
disorders, described in the following section.
6.1. Microencapsulated Probiotics and Colon Cancer. The
potential antitumorigenic properties of a microencapsulated
formulation of L. acidophilus were studied in Min (multiple
intestinal neoplasia) mice carrying a germline Apc mutation
which spontaneously develop numerous pretumoric intesti-
nal neoplasms [29]. The mice were gavaged APA microcap-
sules of L. acidophilus over a period of 12 weeks followed by
the enumeration, the classiﬁcation and the histopathology
of adenomas [29]. Unfortunately, no statistically signiﬁcant
diﬀerence was observed between the treatment and control
group in terms of the number of large intestinal (colonic)
adenomas [29]. On a more positive note, there was a sta-
tistical diﬀerence between the control and treatment groups
followinganalysisofthesmallintestinenumberofadenomas
and gastrointestinal intraepithelial neoplasias [29]. These
preliminary results suggest that microencapsulated probiotic
bacteria could have a role in the development of a successful
colon cancer therapeutic.
6.2. Microencapsulated Probiotics for Use in Cardiovascular
Diseases. Recently, microcapsules containing bacterial cells
have been developed as a cholesterol lowering therapy. Early
research has demonstrated that certain Lactobacilli have a
bile salt hydrolase (BSH) enzyme which can contribute to
a signiﬁcant cholesterol lowering eﬀect in vivo in cardio-
vascular diseases [121]. This enzyme contributes to the
deconjugation of bile salts in the intestine [121]. The oral
deliveryofLactobacillushas,therefore,emergedasapotential
mechanism for inducing cholesterol lowering. Martoni et al.
demonstrated that microencapsulated BSH-active bacteria
are able to survive in a simulated human gastrointestinal
model while maintaining cell viability and enzyme activity,
which would not be possible with the direct delivery of
nonmicroencapsulated bacterial cells [75].8 Journal of Biomedicine and Biotechnology
AnothermicroencapsulatedprobioticLactobacillus dem-
onstrated cholesterol lowering capabilities in hypercholes-
terolemic animals, albeit with a diﬀerent mechanism of
action involving a feruloyl esterase enzyme [122]. Lacto-
bacillus fermentum, a feruloyl esterase active bacterium, was
microencapsulated and delivered to hypercholesterolemic
hamsters twice daily by oral gavage, for a period of 18 weeks
[122]. Following treatment, hamster serum cholesterol, LDL
cholesterol, and the atherogenic index were 21.36%, 31.40%,
and 32.59% lower, respectively, in the treatment group when
compared to the control group [122]. Histological studies
werealso performed and demonstrated that the microencap-
sulated probiotic reduced the progression of atherosclerotic
lesions in the test animals [122]. This probiotic formulation
was hence shown to be eﬀective at managing excessive serum
cholesterol and triglyceride levels [122]. With these results,
the microencapsulation of probiotics is very promising for
the development of a cholesterol-lowering therapeutic in
cardiovascular diseases.
Microencapsulation has the potential to be useful in
other disease applications. It has been shown that, to be
eﬀective at reducing colon tumorigenesis, therapeutic pro-
biotic microorganisms must remain viable in vivo [123]. The
same study that demonstrated that the administration of L.
acidophilus had an inhibitory eﬀect on colon tumorigenesis
showed that the amount of probiotic colonization of the GIT
is directly linked to the rate of inhibition of tumorigenesis
[98]. Since viability is vital to the mechanism of action of
the probiotic, it is crucial to realize that, of the bacteria
ingested, only 1% survive the gastric transit, limiting the
overall therapeutic eﬀect of any orally delivered bacterial
formulation [124]. With unprotected probiotic formulations
already demonstrating therapeutic potential, microencapsu-
lation could prove beneﬁcial in increasing eﬃcacy.
7. Challenges andFutureOutlooks
The gut microbiota is a complex system that has been shown
to inﬂuence health. Although probiotics, prebiotics, and
synbiotics have shown great potential for the treatment of
an u m b e ro fd i s o r d e r s ,t h e r ea r es t i l lan u m b e ro fc h a l l e n g e s
that remain to be addressed before they can be successfully
used to treat/prevent disorders. Microencapsulation has
provided a signiﬁcant advancement in the ﬁeld, allowing
for the delivery of a greater number of viable bacteria
to the GIT. However, a number of issues concerning the
formulation of a microencapsulated probiotic still need to be
addressed before a successful product can be developed. The
process and methods for microencapsulation require further
investigations and optimization. As aforementioned, there
are a number of microencapsulation types being employed,
each varying in eﬃciency and application. Furthermore, the
industry scale production of microencapsulated probiotics,
at a cost-eﬀective level, and investigation of formulation
stability, cell viability and retention of metabolic activity of
the encapsulated bacterial cells requires further development
for speciﬁc bacterial strains and diseases.
Most of the probiotics are strain speciﬁc, they therefore
must be developed and characterised in vitro and evaluated
for their suitability and eﬃcacy in proper animal models and
human clinical trials. Furthermore, a speciﬁc mechanism of
action must be developed for each application so that an
evidence-based probiotic formulation can be designed that
can potentially compete with well-articulated and well-
developed drug formulations. The elucidation of the mech-
anism of action of the probiotic would allow for a better
selection process. As described before, the administration
of bacteria from the same species but of diﬀerent strains
resulted in noncomparable eﬀects, further emphasizing the
importance of mechanistic studies as part of the probiotic
selection process. The variability in experimental design
poses a great challenge in probiotic research that must be
addressed properly. Since the compositions of the gut micro-
ﬂora are not identical, there can be contradicting results
as to the beneﬁcial eﬀect of probiotics on the microbiota
of the GIT. This composition variability also gives rise to
potential diﬃculties in terms of the use of animal models for
the investigation of probiotic formulations. A targeted well-
deﬁned formulation should be developed in which micro-
encapsulation will play a critical role.
There are excellent trials available that demonstrate the
eﬃcacy of these formulations but safety is an issue that
remains to be investigated. As mentioned earlier, rigorous
in vitro and in vivo animal and human clinical studies are
needed to demonstrate the eﬃcacy and the long-term safety
of microencapsulated and other probiotic formulations.
Nevertheless, the literature suggests that probiotics will
lead to eﬃcient therapeutic formulations for the treatment
and/or prevention of a number of animal and human health
disorders.
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